Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)

Sponsor
Ruijin Hospital
Study ID
NCT04508686
Phase
PHASE1
Status
Unknown

Conditions

  • Advanced Cervical Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a single center phase 1 trail to observe safety and efficacy of metronomic capecitabine plus PD-L1 antibody camrelizumab as third-line regimen to treat HER2 negative advanced gastric cancer patients. This study is one of the cohorts of a multi-cohort trial called Combination of Metronomic capecitabine with Camrelizumab for treatment of refractory solid tumor (McCrest) trial.

Key Dates

Start date
Aug 1, 2020
Status verified
Jan 2021
Primary completion
Aug 1, 2022
Completion
Aug 1, 2024

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental
    Capecitabine 500mg bid. po. Camrelizumab 200mg ivgtt. d1 q2w

Primary Outcome Measure

Safety: adverse events as assessed by CTCAE v5.0 [ Time Frame: 48 months ]

Central Contacts